Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS)

被引：14
作者：
Bushnell, CD
Newby, LK
Goldstein, LB
Lin, F
Yaffe, K
Simon, JA
机构：
[1] Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Duke Ctr Cerebrovasc Dis, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA
[4] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27710 USA
[5] Duke Univ, Med Ctr, Ctr Clin Hlth Policy Res, Durham, NC 27710 USA
[6] VA Med Ctr, Durham, NC USA
[7] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[8] Univ Calif San Francisco, Dept Neurol & Psychiat, San Francisco, CA 94143 USA
[9] VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA
来源：
NEUROLOGY | 2004年 / 62卷 / 06期
关键词：
D O I：
10.1212/01.WNL.0000115171.46508.19
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The authors investigated the relationship between statin use and the risk of stroke in the Heart and Estrogen - Progestin Replacement Study (HERS). Despite large reductions in relative risk point estimates, statin use was not associated with differences in the risks of all fatal stroke (relative hazard [RH] 0.52, 95% CI 0.23 to 1.18, p = 0.12), fatal ischemic stroke (RH 0.51, 95% CI 0.18 to 1.45, p = 0.21), fatal hemorrhagic stroke (RH 0.18, 95% CI 0.02 to 1.46, p = 0.11), or TIA (RH 1.32, 95% CI 0.84 to 2.09, p = 0.23).
引用
收藏
页码：968 / 970
页数：3
相关论文
共 10 条
[1]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[2]   Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase [J].
Endres, M ;
Laufs, U ;
Huang, ZH ;
Nakamura, T ;
Huang, P ;
Moskowitz, MA ;
Liao, JK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) :8880-8885
[3]   Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement Study (HERS) [J].
Herrington, DM ;
Vittinghoff, E ;
Lin, F ;
Fong, J ;
Harris, F ;
Hunninghake, D ;
Bittner, V ;
Schrott, HG ;
Blumenthal, RS ;
Levy, R .
CIRCULATION, 2002, 105 (25) :2962-2967
[4]   Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women [J].
Hulley, S ;
Grady, D ;
Bush, T ;
Furberg, C ;
Herrington, D ;
Riggs, B ;
Vittinghoff, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (07) :605-613
[5]  
PEDERSEN TR, 1994, LANCET, V344, P1383
[6]   Reduction of stroke incidence after myocardial infarction with pravastatin -: The cholesterol and recurrent events (CARE) study [J].
Plehn, JF ;
Davis, BR ;
Sacks, FM ;
Rouleau, JL ;
Pfeffer, MA ;
Bernstein, V ;
Cuddy, TE ;
Moyé, LA ;
Piller, LB ;
Rutherford, J ;
Simpson, LM ;
Braunwald, E .
CIRCULATION, 1999, 99 (02) :216-223
[7]   Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial [J].
Rossouw, JE ;
Anderson, GL ;
Prentice, RL ;
LaCroix, AZ ;
Kooperberg, C ;
Stefanick, ML ;
Jackson, RD ;
Beresford, SAA ;
Howard, BV ;
Johnson, KC ;
Kotchen, JM ;
Ockene, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (03) :321-333
[8]   Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study [J].
Sillesen, H .
CEREBROVASCULAR DISEASES, 2003, 16 (04) :389-395
[9]   Postmenopausal hormone therapy and risk of stroke - The Heart and Estrogen-progestin Replacement Study (HERS) [J].
Simon, JA ;
Hsia, J ;
Cauley, JA ;
Richards, C ;
Harris, F ;
Fong, J ;
Barrett-Connor, E ;
Hulley, SB .
CIRCULATION, 2001, 103 (05) :638-642
[10]  
Tonkin A, 1998, NEW ENGL J MED, V339, P1349
1